It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Type 2 diabetes is characterized by progressive β cell dysfunction, with lipotoxicity playing a possible pathogenetic role. Palmitate is often used to examine the direct effects of lipotoxicity and it may cause mitochondrial alterations by activating protein acetylation. However, it is unknown whether palmitate influences protein acetylation in β cells. We investigated lysine acetylation in mitochondrial proteins from INS-1E β cells (INS-1E) and in proteins from human pancreatic islets (HPI) after 24 h palmitate exposure. First, we confirmed that palmitate damages β cells and demonstrated that chemical inhibition of deacetylation also impairs INS-1E function and survival. Then, by 2-D gel electrophoresis, Western Blot and Liquid Chromatography-Mass Spectrometry we evaluated the effects of palmitate on protein acetylation. In mitochondrial preparations from palmitate-treated INS-1E, 32 acetylated spots were detected, with 13 proteins resulting over-acetylated. In HPI, 136 acetylated proteins were found, of which 11 were over-acetylated upon culture with palmitate. Interestingly, three proteins, glutamate dehydrogenase, mitochondrial superoxide dismutase, and SREBP-1, were over-acetylated in both INS-1E and HPI. Therefore, prolonged exposure to palmitate induces changes in β cell protein lysine acetylation and this modification could play a role in causing β cell damage. Dysregulated acetylation may be a target to counteract palmitate-induced β cell lipotoxicity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Department of Pharmacy, University of Pisa; Via Bonanno 6, Pisa, Italy; Department of Clinical and Experimental Medicine, Islet Cell Laboratory, Via Savi 10, Pisa, Italy
2 Department of Clinical and Experimental Medicine, Islet Cell Laboratory, Via Savi 10, Pisa, Italy
3 Proteomics and Metabonomics Unit, IRCCS-Fondazione Santa Lucia; Via del Fosso di Fiorano 64/65, Rome, Italy; Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio of Chieti-Pescara; Via Dei Vestini 31, Chieti, Italy
4 Department of Pharmacy, University of Pisa; Via Bonanno 6, Pisa, Italy
5 ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium; Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium
6 Proteomics and Metabonomics Unit, IRCCS-Fondazione Santa Lucia; Via del Fosso di Fiorano 64/65, Rome, Italy; Istituto di Biochimica e Biochimica Clinica, Università Cattolica; Largo Francesco Vito 1, Roma, Italy